{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T11:19:55Z","timestamp":1793186395528,"version":"4.5.0"},"reference-count":106,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2021,2,23]]},"DOI":"10.1001\/jama.2020.26858","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T11:49:04Z","timestamp":1614080944000},"page":"765","source":"Crossref","is-referenced-by-count":1192,"title":["Diagnosis and Treatment of Multiple Sclerosis"],"prefix":"10.1001","volume":"325","author":[{"given":"Marisa P.","family":"McGinley","sequence":"first","affiliation":[{"name":"Cleveland Clinic Mellen Center, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn H.","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Mellen Center, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander D.","family":"Rae-Grant","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Mellen Center, Cleveland, Ohio"},{"name":"Now with Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"jrv200019r1","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ana.v78.5","article-title":"Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque.","volume":"78","author":"Frischer","year":"2015","journal-title":"Ann Neurol"},{"issue":"5","key":"jrv200019r2","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1056\/NEJM199801293380502","article-title":"Axonal transection in the lesions of multiple sclerosis.","volume":"338","author":"Trapp","year":"1998","journal-title":"N Engl J Med"},{"issue":"10","key":"jrv200019r3","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","article-title":"The prevalence of MS in the United States: a population-based estimate using health claims data.","volume":"92","author":"Wallin","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"jrv200019r4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016149","article-title":"Smoking and multiple sclerosis: an updated meta-analysis.","volume":"6","author":"Handel","year":"2011","journal-title":"PLoS One"},{"issue":"9","key":"jrv200019r5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012496","article-title":"An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis.","volume":"5","author":"Handel","year":"2010","journal-title":"PLoS One"},{"issue":"6","key":"jrv200019r6","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1212\/WNL.0b013e31820af93d","article-title":"Sun exposure and vitamin D are independent risk factors for CNS demyelination.","volume":"76","author":"Lucas","year":"2011","journal-title":"Neurology"},{"issue":"10","key":"jrv200019r7","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1177\/1352458513483889","article-title":"Childhood body mass index and multiple sclerosis risk: a long-term cohort study.","volume":"19","author":"Munger","year":"2013","journal-title":"Mult Scler"},{"issue":"23","key":"jrv200019r8","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1001\/jama.296.23.2832","article-title":"Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis.","volume":"296","author":"Munger","year":"2006","journal-title":"JAMA"},{"issue":"11","key":"jrv200019r9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003926","article-title":"Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effects.","volume":"9","author":"Patsopoulos","year":"2013","journal-title":"PLoS Genet"},{"issue":"11","key":"jrv200019r10","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1212\/WNL.0000000000000768","article-title":"Atlas of Multiple Sclerosis 2013: a growing global problem with widespread inequity.","volume":"83","author":"Browne","year":"2014","journal-title":"Neurology"},{"issue":"23","key":"jrv200019r11","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1056\/NEJMoa1100648","article-title":"Inflammatory cortical demyelination in early multiple sclerosis.","volume":"365","author":"Lucchinetti","year":"2011","journal-title":"N Engl J Med"},{"issue":"pt 5","key":"jrv200019r12","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/brain\/awp070","article-title":"The relation between inflammation and neurodegeneration in multiple sclerosis brains.","volume":"132","author":"Frischer","year":"2009","journal-title":"Brain"},{"key":"jrv200019r13","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3389\/fimmu.2015.00636","article-title":"B cells in the multiple sclerosis central nervous system: trafficking and contribution to CNS-compartmentalized inflammation.","volume":"6","author":"Michel","year":"2015","journal-title":"Front Immunol"},{"issue":"2","key":"jrv200019r14","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald Criteria.","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"11","key":"jrv200019r15","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1001\/jamaneurol.2018.2160","article-title":"Application of the 2017 revised McDonald Criteria for multiple sclerosis to patients with a typical clinically isolated syndrome.","volume":"75","author":"van der Vuurst de Vries","year":"2018","journal-title":"JAMA Neurol"},{"issue":"4","key":"jrv200019r16","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ana.v80.4","article-title":"Long-term evolution of multiple sclerosis disability in the treatment era.","volume":"80","author":"Cree","year":"2016","journal-title":"Ann Neurol"},{"issue":"20","key":"jrv200019r17","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJM200011163432001","article-title":"Relapses and progression of disability in multiple sclerosis.","volume":"343","author":"Confavreux","year":"2000","journal-title":"N Engl J Med"},{"issue":"pt 1","key":"jrv200019r18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/brain\/112.1.133","article-title":"The natural history of multiple sclerosis: a geographically based study, I: clinical course and disability.","volume":"112","author":"Weinshenker","year":"1989","journal-title":"Brain"},{"issue":"pt 7","key":"jrv200019r19","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1093\/brain\/awq118","article-title":"The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.","volume":"133","author":"Scalfari","year":"2010","journal-title":"Brain"},{"issue":"3","key":"jrv200019r20","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1212\/WNL.0000000000001718","article-title":"Effect of comorbidity on mortality in multiple sclerosis.","volume":"85","author":"Marrie","year":"2015","journal-title":"Neurology"},{"issue":"4","key":"jrv200019r21","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1177\/135245859900500409","article-title":"The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment.","volume":"5","author":"Fischer","year":"1999","journal-title":"Mult Scler"},{"issue":"11","key":"jrv200019r22","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"7","key":"jrv200019r23","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(13)70103-0","article-title":"MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials.","volume":"12","author":"Sormani","year":"2013","journal-title":"Lancet Neurol"},{"issue":"pt 9","key":"jrv200019r24","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1093\/brain\/awr182","article-title":"Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis.","volume":"134","author":"Howell","year":"2011","journal-title":"Brain"},{"issue":"1","key":"jrv200019r25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40120-017-0063-y","article-title":"Number needed to treat in multiple sclerosis clinical trials.","volume":"6","author":"Okwuokenye","year":"2017","journal-title":"Neurol Ther"},{"issue":"4","key":"jrv200019r26","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1212\/WNL.43.4.655","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial.","volume":"43","author":"IFNB Multiple Sclerosis Study Group","year":"1993","journal-title":"Neurology"},{"issue":"9139","key":"jrv200019r27","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis.","volume":"352","author":"PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group","year":"1998","journal-title":"Lancet"},{"issue":"7","key":"jrv200019r28","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S1474-4422(14)70068-7","article-title":"Pegylated interferon \u00df-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol"},{"issue":"13","key":"jrv200019r29","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJM200009283431301","article-title":"Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis.","volume":"343","author":"Jacobs","year":"2000","journal-title":"N Engl J Med"},{"issue":"3","key":"jrv200019r30","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/(ISSN)1531-8249","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis.","volume":"39","author":"Jacobs","year":"1996","journal-title":"Ann Neurol"},{"issue":"7","key":"jrv200019r31","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","article-title":"Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial.","volume":"45","author":"Johnson","year":"1995","journal-title":"Neurology"},{"issue":"5","key":"jrv200019r32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"jrv200019r33","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.","volume":"362","author":"Cohen","year":"2010","journal-title":"N Engl J Med"},{"issue":"10127","key":"jrv200019r34","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"jrv200019r35","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurol"},{"issue":"12","key":"jrv200019r36","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.","volume":"367","author":"Fox","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"jrv200019r37","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.","volume":"367","author":"Gold","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"jrv200019r38","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40263-020-00700-0","article-title":"Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: results from the randomized, double-blind, phase III EVOLVE-MS-2 study.","volume":"34","author":"Naismith","year":"2020","journal-title":"CNS Drugs"},{"issue":"14","key":"jrv200019r39","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis.","volume":"365","author":"O\u2019Connor","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"jrv200019r40","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol"},{"issue":"5","key":"jrv200019r41","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"jrv200019r42","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"jrv200019r43","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis.","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"jrv200019r44","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus Teriflunomide in Multiple Sclerosis.","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"issue":"9856","key":"jrv200019r45","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"issue":"9856","key":"jrv200019r46","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"issue":"2","key":"jrv200019r47","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies.","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol"},{"issue":"11","key":"jrv200019r48","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.","volume":"18","author":"Cohen","year":"2019","journal-title":"Lancet Neurol"},{"issue":"11","key":"jrv200019r49","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1212\/WNL.0000000000004354","article-title":"Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings.","volume":"89","author":"Coles","year":"2017","journal-title":"Neurology"},{"issue":"4","key":"jrv200019r50","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S1474-4422(19)30076-6","article-title":"Intracerebral haemorrhage during alemtuzumab administration.","volume":"18","author":"Azevedo","year":"2019","journal-title":"Lancet Neurol"},{"issue":"20","key":"jrv200019r51","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy.","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv200019r52","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1086\/cid.2006.43.issue-1","article-title":"Infectious complications associated with alemtuzumab use for lymphoproliferative disorders.","volume":"43","author":"Martin","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"2","key":"jrv200019r53","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jama.2018.20588","article-title":"Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis.","volume":"321","author":"Brown","year":"2019","journal-title":"JAMA"},{"issue":"9997","key":"jrv200019r54","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/S0140-6736(15)61137-0","article-title":"Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.","volume":"386","author":"Le Page","year":"2015","journal-title":"Lancet"},{"issue":"10","key":"jrv200019r55","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8101623","article-title":"Therapeutic apheresis in acute relapsing multiple sclerosis: current evidence and unmet needs\u2014a systematic review.","volume":"8","author":"Rolfes","year":"2019","journal-title":"J Clin Med"},{"issue":"10","key":"jrv200019r56","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1136\/jnnp-2016-313760","article-title":"Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study.","volume":"87","author":"Kister","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"jrv200019r57","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jns.2018.06.001","article-title":"Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.","volume":"391","author":"Kister","year":"2018","journal-title":"J Neurol Sci"},{"issue":"5","key":"jrv200019r58","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1056\/NEJM199807303390501","article-title":"Rate of pregnancy-related relapse in multiple sclerosis.","volume":"339","author":"Confavreux","year":"1998","journal-title":"N Engl J Med"},{"issue":"5","key":"jrv200019r59","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/nrneurol.2015.53","article-title":"Multiple sclerosis and pregnancy in the \u201ctreatment era\u201d.","volume":"11","author":"Vukusic","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"jrv200019r60","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102241","article-title":"Change in pregnancy-associated multiple sclerosis relapse rates over time: a meta-analysis.","volume":"44","author":"Dobson","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"jrv200019r61","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/bdra.v100.6","article-title":"Corticosteroid use and risk of orofacial clefts.","volume":"100","author":"Skuladottir","year":"2014","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"issue":"10","key":"jrv200019r62","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1007\/s00415-012-6553-z","article-title":"Breastfeeding and multiple sclerosis relapses: a meta-analysis.","volume":"259","author":"Pakpoor","year":"2012","journal-title":"J Neurol"},{"key":"jrv200019r63","article-title":"Management of multiple sclerosis in the breastfeeding mother.","volume":"2016","author":"Almas","year":"2016","journal-title":"Mult Scler Int"},{"issue":"13","key":"jrv200019r64","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1212\/WNL.0b013e3181d6b125","article-title":"Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis.","volume":"74","author":"Marrie","year":"2010","journal-title":"Neurology"},{"issue":"23","key":"jrv200019r65","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1212\/WNL.0000000000001658","article-title":"Cardiorespiratory fitness and brain volume and white matter integrity: the CARDIA study.","volume":"84","author":"Zhu","year":"2015","journal-title":"Neurology"},{"issue":"2","key":"jrv200019r66","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1212\/01.wnl.0000333252.78173.5f","article-title":"Comorbidity delays diagnosis and increases disability at diagnosis in MS.","volume":"72","author":"Marrie","year":"2009","journal-title":"Neurology"},{"issue":"15","key":"jrv200019r67","doi-asserted-by":"publisher","first-page":"e1316","DOI":"10.1212\/WNL.0000000000005302","article-title":"Psychiatric comorbidity is associated with disability progression in multiple sclerosis.","volume":"90","author":"McKay","year":"2018","journal-title":"Neurology"},{"issue":"3","key":"jrv200019r68","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/1352458508099477","article-title":"The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and undertreated.","volume":"15","author":"Marrie","year":"2009","journal-title":"Mult Scler"},{"issue":"4","key":"jrv200019r69","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1136\/practneurol-2013-000735","article-title":"Recommendations on diagnosis and treatment of depression in patients with multiple sclerosis.","volume":"14","author":"Fragoso","year":"2014","journal-title":"Pract Neurol"},{"issue":"1","key":"jrv200019r70","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/1352458506071161","article-title":"Anxiety disorders and their clinical correlates in multiple sclerosis patients.","volume":"13","author":"Korostil","year":"2007","journal-title":"Mult Scler"},{"issue":"8","key":"jrv200019r71","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1177\/1352458508092807","article-title":"Prevalence of sleep problems in individuals with multiple sclerosis.","volume":"14","author":"Bamer","year":"2008","journal-title":"Mult Scler"},{"issue":"9","key":"jrv200019r72","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.5664\/jcsm.4044","article-title":"The underdiagnosis of sleep disorders in patients with multiple sclerosis.","volume":"10","author":"Brass","year":"2014","journal-title":"J Clin Sleep Med"},{"issue":"3","key":"jrv200019r73","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1191\/1352458505ms1157oa","article-title":"25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis.","volume":"11","author":"Soilu-H\u00e4nninen","year":"2005","journal-title":"Mult Scler"},{"issue":"12","key":"jrv200019r74","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1001\/jamaneurol.2015.2742","article-title":"Association of vitamin D levels with multiple sclerosis activity and progression in patients receiving interferon Beta-1b.","volume":"72","author":"Fitzgerald","year":"2015","journal-title":"JAMA Neurol"},{"issue":"6","key":"jrv200019r75","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1177\/1352458514551780","article-title":"Risk factors for multiple sclerosis, neuromyelitis optica and transverse myelitis.","volume":"21","author":"Simon","year":"2015","journal-title":"Mult Scler"},{"issue":"4","key":"jrv200019r76","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1177\/1352458507085551","article-title":"Lifetime and actual prevalence of pain and headache in multiple sclerosis.","volume":"14","author":"Martinelli Boneschi","year":"2008","journal-title":"Mult Scler"},{"issue":"5","key":"jrv200019r77","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1191\/1352458504ms1085oa","article-title":"Prevalence and treatment of spasticity reported by multiple sclerosis patients.","volume":"10","author":"Rizzo","year":"2004","journal-title":"Mult Scler"},{"issue":"3","key":"jrv200019r78","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1191\/1352458503ms904oa","article-title":"Fatigue associated with multiple sclerosis: diagnosis, impact and management.","volume":"9","author":"Bakshi","year":"2003","journal-title":"Mult Scler"},{"issue":"6","key":"jrv200019r79","first-page":"3","article-title":"Prevalence of multiple sclerosis symptoms across lifespan: data from the NARCOMS Registry.","volume":"5","author":"Fox","year":"2015","journal-title":"Neurodegener Dis Manag"},{"issue":"1-2","key":"jrv200019r80","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jns.2011.07.015","article-title":"Sleep disturbances in multiple sclerosis.","volume":"309","author":"Caminero","year":"2011","journal-title":"J Neurol Sci"},{"issue":"2","key":"jrv200019r81","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1517\/14656566.2012.647767","article-title":"Management options in multiple sclerosis-associated fatigue.","volume":"13","author":"Amato","year":"2012","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"jrv200019r82","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1212\/WNL.41.5.685","article-title":"Cognitive dysfunction in multiple sclerosis, I: frequency, patterns, and prediction.","volume":"41","author":"Rao","year":"1991","journal-title":"Neurology"},{"issue":"10","key":"jrv200019r83","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1001\/archneur.58.10.1602","article-title":"Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years.","volume":"58","author":"Amato","year":"2001","journal-title":"Arch Neurol"},{"issue":"3","key":"jrv200019r84","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S0022-5347(01)61760-9","article-title":"Multiple sclerosis and the urologist.","volume":"161","author":"Litwiller","year":"1999","journal-title":"J Urol"},{"issue":"2","key":"jrv200019r85","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/BF00887825","article-title":"Prevalence of bowel dysfunction in patients with multiple sclerosis and bladder dysfunction.","volume":"242","author":"Chia","year":"1995","journal-title":"J Neurol"},{"issue":"6","key":"jrv200019r86","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/0016-5085(90)91087-M","article-title":"Prevalence of bowel dysfunction in multiple sclerosis: a population survey.","volume":"98","author":"Hinds","year":"1990","journal-title":"Gastroenterology"},{"issue":"1-2","key":"jrv200019r87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0022-510X(01)00493-2","article-title":"Sexual dysfunction in multiple sclerosis: a 2-year follow-up study.","volume":"187","author":"Zorzon","year":"2001","journal-title":"J Neurol Sci"},{"issue":"12","key":"jrv200019r88","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1002\/mds.v19:12","article-title":"Prevalence of tremor in multiple sclerosis and associated disability in the Olmsted County population.","volume":"19","author":"Pittock","year":"2004","journal-title":"Mov Disord"},{"issue":"pt 4","key":"jrv200019r89","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/brain\/124.4.720","article-title":"A study of tremor in multiple sclerosis.","volume":"124","author":"Alusi","year":"2001","journal-title":"Brain"},{"key":"jrv200019r90","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.msard.2018.08.003","article-title":"The frequency of dysphagia and its impact on adults with multiple sclerosis based on patient-reported questionnaires.","volume":"25","author":"Alali","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"jrv200019r91","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1001\/archneur.1997.00550170015009","article-title":"Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis.","volume":"54","author":"Mohr","year":"1997","journal-title":"Arch Neurol"},{"issue":"6","key":"jrv200019r92","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/bpa.2017.27.issue-6","article-title":"Age-related small vessel disease: a potential contributor to neurodegeneration in multiple sclerosis.","volume":"27","author":"Geraldes","year":"2017","journal-title":"Brain Pathol"},{"issue":"3","key":"jrv200019r93","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1177\/1352458513507358","article-title":"Effects of exercise on fitness and cognition in progressive MS: a randomized, controlled pilot trial.","volume":"20","author":"Briken","year":"2014","journal-title":"Mult Scler"},{"issue":"20","key":"jrv200019r94","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1212\/WNL.0000000000000433","article-title":"Brain reserve and cognitive reserve protect against cognitive decline over 4.5 years in MS.","volume":"82","author":"Sumowski","year":"2014","journal-title":"Neurology"},{"issue":"8","key":"jrv200019r95","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1177\/1352458508093615","article-title":"Smoking worsens the prognosis in multiple sclerosis.","volume":"14","author":"Sundstr\u00f6m","year":"2008","journal-title":"Mult Scler"},{"issue":"12","key":"jrv200019r96","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11940-019-0601-2","article-title":"Pain management in multiple sclerosis: a review of available treatment options.","volume":"21","author":"Aboud","year":"2019","journal-title":"Curr Treat Options Neurol"},{"issue":"12","key":"jrv200019r97","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1111\/ene.2007.14.issue-12","article-title":"A prospective study of patterns of fatigue in multiple sclerosis.","volume":"14","author":"Lerdal","year":"2007","journal-title":"Eur J Neurol"},{"issue":"3","key":"jrv200019r98","first-page":"815","article-title":"Symptom management and lifestyle modifications in multiple sclerosis.","volume":"22","author":"Coyle","year":"2016","journal-title":"Continuum (Minneap Minn)"},{"issue":"2","key":"jrv200019r99","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2018.18743","article-title":"Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial.","volume":"321","author":"Burt","year":"2019","journal-title":"JAMA"},{"issue":"10","key":"jrv200019r100","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1212\/WNL.0000000000001329","article-title":"Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial.","volume":"84","author":"Mancardi","year":"2015","journal-title":"Neurology"},{"issue":"2","key":"jrv200019r101","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1001\/jamaneurol.2014.3780","article-title":"High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.","volume":"72","author":"Nash","year":"2015","journal-title":"JAMA Neurol"},{"issue":"pt B","key":"jrv200019r102","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.neuropharm.2015.08.028","article-title":"Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis.","volume":"110","author":"Sedel","year":"2016","journal-title":"Neuropharmacology"},{"issue":"10111","key":"jrv200019r103","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1016\/S0140-6736(17)32346-2","article-title":"Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial.","volume":"390","author":"Green","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"jrv200019r104","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S1474-4422(19)30137-1","article-title":"Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.","volume":"18","author":"Cadavid","year":"2019","journal-title":"Lancet Neurol"},{"key":"jrv200019r105","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ebiom.2018.02.002","article-title":"Phase I trial of intrathecal mesenchymal stem cell\u2013derived neural progenitors in progressive multiple sclerosis.","volume":"29","author":"Harris","year":"2018","journal-title":"EBioMedicine"},{"issue":"12","key":"jrv200019r106","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S1474-4422(20)30347-1","article-title":"Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"19","author":"Cree","year":"2020","journal-title":"Lancet Neurol"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2776694\/jama_mcginley_2021_rv_200019_1622223670.83305.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T19:33:23Z","timestamp":1622576003000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2776694"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2021,2,23]]},"references-count":106,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,2,23]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2020.26858","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,23]]}}}